Reduction by Dietary Matrix Metalloproteinase Inhibitor BAY 12-9566N of Neoplastic Development Induced by Diethylnitrosamine, N-nitrosodimethylamine, or 7,12-dimethylbenz(a)anthracene in Rats

REFERENCES

• Beckett R. P., Davidson A. H., Drummond A. H., Huxley P., Whittaker M. Recent advances in matrix metalloproteinase inhibitor research. Drug Disc. Ther. 1996; 1: 16–26
   Google Scholar
• Brown P. D. Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv. Enzyme Regul. 1995; 35: 293–301
   PubMedGoogle Scholar
• Egeblad M., Web A. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002; 2: 161–174
   PubMed Web of Science ®Google Scholar
• Erlichman C., Adjei A. A., Alberts S. R., Sloan J. A., Goldberg R. M., Pitot H. C., Rubin J., Atherton P. J., Klee G. G., Humphrey R. Phase I study of the matrix metalloproteinase inhibitor, BAY 12–9566. Ann. Oncol. 2001; 12: 389–395
   PubMed Web of Science ®Google Scholar
• Gabriel K. R. A simple method of multiple comparisons of means. J. Am. Stat. Assoc. 1978; 73: 724–729
   Web of Science ®Google Scholar
• Genter M. B., Burman D. M., Vijayakumar S., Ebert C. L., Aronow B. J. Genomic analysis of alachlor-induced oncogenesis in rat olfactory mucosa. Physiol. Genom. 2002; 12: 35–45
   PubMed Web of Science ®Google Scholar
• Genter M. B., Warner B. M., Krell H. W., Bolon B. Reduction of Alachlor-induced olfactory mucosal neoplasms by the matrix metalloproteinase inhibitor RO28-2653. Toxicol. Pathol. 2005; 33: 593–539
   PubMed Web of Science ®Google Scholar
• Gomez D. E., Alonso D. F., Yoshiji H., Thorgierrson U. P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 1997; 74: 111–122
   PubMed Web of Science ®Google Scholar
• Goss K. J., Brown P. D., Matrisian L. M. Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Intl. J. Cancer. 1998; 78: 629–635
   PubMed Web of Science ®Google Scholar
• Grams F., Branstetter H., D'Alo S., Geppert D., Krell H. W., Leinert H., Livi V., Menta E., Oliva A., Zimmerman G. Pyrimidine-2,4-6-triones: a new effective and selective class of matrix metalloproteinase inhibitors. Biol. Chem. 2001; 382: 1277–1285
   PubMed Web of Science ®Google Scholar
• Hirte H., Goel P., Seymour L., Huan S., Stewart D., Yau J., Arnold A., Holohan S., Waterfield B., Bates S., Bennett K., Walsh W., Elias I. A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann. Oncol. 2000; 11: 1579–1584
   PubMed Web of Science ®Google Scholar
• Iatropoulos M. J. Accelerated rodent bioassy predictive of chemical carcinogenesis. Exp. Toxicol. Pathol. 1992; 44: 481–487
   PubMed Web of Science ®Google Scholar
• Iatropoulos M. J., Williams G. M., Wang C. X., Brunnemann K. D., Leber A. P. Assessment of chronic toxicity and carcinogenicity in rats of Wingstay®100, a rubber antioxidant/antizonant. Exp. Toxicol. Pathol. 1997; 49: 153–165
   PubMed Web of Science ®Google Scholar
• Iatropoulos M. J., Jeffrey A. M., Enzmann H. G., von Keutz E., Schlueter G., Williams G. M. Assessment of chronic toxicity and carcinogenicity in an accelerated cancer bioassy in rats of moxifloxacin, a quinololone antibiotic. Exp. Toxicol. Pathol. 2001; 53: 345–357
   PubMed Web of Science ®Google Scholar
• Iatropoulos M. J., Wang C. X., von Keutz E., Williams G. M. Assessment of chronic toxicity and carcinogenicity in an accelerated cancer bioassay in rats of Nifurtimox, an antitrypanosomiasis drug. Exp. Toxicol. Pathol. 2006; 57: 252–259
   Google Scholar
• Levy D. E., Ezrin A. M. Matrix metalloproteinase inhibiting drugs. Emerg. Drugs 1997; 2: 205–230
   Google Scholar
• Liotta L., Stetler-Stevenson W. Metalloproteinases and cancer invasion. Semin. Cancer Biol. 1990; 1: 99–106
   PubMedGoogle Scholar
• Lynch C. C., Matrisian L. M. Matrix metalloproteinases in tumor-host communication. Differentiation 2002; 70: 561–573
   PubMed Web of Science ®Google Scholar
• Mäkelä M., Larjava H., Pirilä E., Maisi P., Salo T., Sorsa T., Vitto V-J. Matrix metalloproteinase 2 (gelatinase A) is related to migration of keratinocytes. Exp. Cell Res. 1999; 251: 67–78
   PubMed Web of Science ®Google Scholar
• Maquoi E., Sounni N. E., Devy L, Olivier F., Frankenne F., Krell H. W., Grams F., Foidart J. N., Noel A. Anti invasive, antitumoral, and antianiogenic efficacy of a pyrimidine-2-4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin. Cancer Res. 2004; 10: 4038–4047
   PubMed Web of Science ®Google Scholar
• Ogata T., Teshima T., Kagawa K., Hishikawa Y., Takahashi Y., Kawaguchi A., Suzumoto Y., Nojima K., Furusawa Y., Matsuura N. Particle irradiation suppresses metastatic potential of cancer cells. Cancer Res. 2005; 65(1)113–120
   PubMed Web of Science ®Google Scholar
• Peto R., Pike M. C., Day N. E., Gray R. G., Lee P. N., Parish S., Peto, Wahrendorf J. Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. Long-Term and Short-Term Screening Assays for Carcinogens: A Critical Appraisal, R. Montesano, H. Bartsch, L. Tomatis. IARC, LyonFrance 1980; 311–426, IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Suppl. 2.
   Google Scholar
• Shepherd F. A., Giaccone G., Seymour L., Debruyne C., Bezjak A., Hirsch V., Smylie M., Rubin S., Martins H., Lamont A., Krzakowski J., Sadura A., Zee B. Prospective, randomized, double-blind placebo controlled trial of Marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada—Clinical Trials group and the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 2002; 20(22)4434–4439
   PubMed Web of Science ®Google Scholar
• Stamenkovic I. Matrix metalloproteinase in tumor invasion and metastasis. Semin. Cancer Biol. 2002; 10: 415–433
   Web of Science ®Google Scholar
• Stamenkovic I. Extracellular matrix remodeling: the role of matrix metalloproteinases. J. Pathol. 2003; 200: 448–464
   PubMed Web of Science ®Google Scholar
• Sternlicht J. D., Werb Z. Matrix metalloproteinases. Guidebook to the Extracellular Matrix, Anchor and Adhesion Proteins, T. Kreis, R. Vale. Oxford University Press, New York 1999; 503–603
   Google Scholar
• Sternlicht M. D., Werb Z. How matrix metalloproteinases regulate cell behavior. Ann. Rev. Cell Dev. Biol. 2001; 17: 463–516
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson W. G., Yu A. E. Proteases in invasion: matrix metalloproteinases. Semin. Cancer Biol. 2001; 11: 143–152
   PubMed Web of Science ®Google Scholar
• Williams G. M., Iatropoulos M. J. Principles of testing for carcinogenic activity. Principles and Methods of Toxicology, W. Hayes, Philadelphia, Pennsylvania, USA 2001; 959–1000
   Google Scholar
• Williams G. M., Iatropoulos M. J., Weisburger J. H. Chemical carcinogen mechanisms of action and implications for testing methodology. Exp. Toxicol. Pathol. 1996; 48: 101–111
   PubMed Web of Science ®Google Scholar
• Wyatt C. A., Geoghegan J. C., Brinckerhoff C. E. Short hairpin RNA-mediated inhibition of matrix metalloproteinase-1 in MDA-231 Cells: effects on matrix destruction and tumor growth. Cancer Res. 2005; 65(23)11101–11108
   PubMed Web of Science ®Google Scholar
• Xu X., Wang Y., Chen Z., Sternlicht J. D., Hidalgo M., Steffensen B. Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. Cancer Res. 2005; 65(1)130–137
   PubMed Web of Science ®Google Scholar
• Zhou Y., Yu C., Miao X., Tan W., Liang G., Xiong P., Sun T., Lix D. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 2004; 25(3)399–404
   PubMed Web of Science ®Google Scholar